Vitreoretinal interface proteins (VRI proteins)

Vitreoretinal interface proteins consist of a specialized network of extracellular matrix (ECM) molecules, primarily laminin, fibronectin, and various collagen types (Type IV in the internal limiting membrane and Type II in the vitreous), that mediate the strong adhesion between the posterior vitreous cortex and the retina (Gandorfer et al., 2008 [1]). These proteins are essential for maintaining the structural stability of the eye; however, incomplete or abnormal vitreous separation during aging can lead to pathological conditions such as vitreomacular traction (VMT) and macular holes, which cause significant visual distortion and loss (Sebag, 1998 [2]). Pharmacological targeting of these proteins, most notably through the recombinant protease ocriplasmin (Jetrea), aims to achieve "pharmacological vitreolysis" by specifically degrading the proteinaceous "glue" at the interface (Stalmans et al., 2012 [4]). By cleaving laminin and fibronectin, these therapies facilitate the clean separation of the vitreous from the macula, providing a non-surgical alternative to pars plana vitrectomy. Despite their therapeutic utility, these agents require careful clinical monitoring due to potential side effects such as retinal tears, zonular fiber degradation leading to lens subluxation, and transient changes in retinal function (FDA Jetrea Label [3]).

Other names

Vitreoretinal junction proteinsVitreoretinal extracellular matrix componentsInternal limiting membrane proteinsVitreous attachment proteins

Enzymatic proteolysis of laminin, fibronectin, and collagen to induce posterior vitreous detachment and relieve mechanical traction on the retina.